ClinicalTrials.gg
CompletedNCT00473512Updated Mar 27, 2014Results posted

A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone Therapy

A Phase 1/2 interventional study of Abiraterone acetate and Abiraterone acetate MTD in Prostatic Neoplasms, sponsored by Cougar Biotechnology, Inc.. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-03-27.

Sponsored by Cougar Biotechnology, Inc. (part of Johnson & Johnson) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
54
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms — 12 open to participants now, 29 under way, 4 of them phase 3. Abiraterone Acetate · Prostatic Neoplasms.

Enrollment
50th of 98
54 · median 56
Started
2005
the only one that year
Phase 1/2
8 of 98
none open now
Registered
1st of 98
by date
Lead sponsor
6 of 98
Cougar Biotechnology, Inc.

Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, this one is the 50th largest by enrollment, is the only one that started in 2005, is one of 8 in phase 1/2, and was the 1st registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

12 of the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About Abiraterone Acetate

Abiraterone Acetate: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine the maximum tolerated dose and evaluate the safety, tolerability, and activity at the recommended dose (maximum tolerated dose [MTD]) of abiraterone acetate (also known as CB7630) in participants with hormone refractory prostate (gland that makes fluid that aids movement of sperm) cancer (HRPC).

Read the detailed description

This is an open-label (all people know the identity of the intervention) study to evaluate the safety, tolerability, and recommended dose of abiraterone acetate taken orally (by mouth), once daily in participants with HRPC. The study will consist of a dose escalation stage (Phase 1) that will be conducted to determine the MTD of abiraterone and an activity evaluation stage (Phase 2) to evaluate the activity of abiraterone in participants with HRPC. Escalated doses of abiraterone (starting at 250 milligram [mg] up to a maximum of 2000 mg) will be given for 28-day treatment periods to determine the MTD. Participants will be given MTD of abiraterone for up to 12 cycles (28 day each) in Phase 2 of the study. Participants' safety will be monitored throughout the study.

03

Conditions studied

  • Prostatic Neoplasms

Browse trials for

Keywords

  • Abiraterone acetate
  • CB7630
  • Prostatic neoplasms
  • Hormone refractory prostate cancer
  • Castration resistant prostate cancer
  • Castration refractory prostate cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologically (pertaining to the disease status of body tissues or cells) documented adenocarcinoma of the prostate, clinically (not responding to treatment) or resistant to hormone therapy, as documented by progression following at least one hormonal therapy
  • Prostate specific antigen (PSA) evidence for progressive prostate cancer
  • Participants who were withdrawn from anti-androgen therapy less than 6 months prior to inclusion in the study require one PSA higher than the last pre-withdrawal PSA or 2 increases in PSA documented after the post-withdrawal nadir(value) greater than or equal to 4 weeks from treatment withdrawal if treated with flutamide and greater than or equal to 6 weeks if treated with bicalutamide or nilutamide
  • (ECOG) performance status score equal to 0 or 1
  • of greater than or equal to12 week

Exclusion criteria

Exclusion Criteria:

  • Participants with central nervous system (the brain and spinal cord) disease and/or
  • No currently active second (cancer or other progressively enlarging and spreading tumor) other than non-melanoma skin cancer
  • Myocardial infarction within the 6 months prior to start of study
  • No active or uncontrolled disease (disorder in which a person's immune system attacks parts of his or her own body) that may require therapy during protocol treatment
  • Major surgery or significant traumatic injury within 4 weeks of start of study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Abiraterone acetate

    Abiraterone acetate 250 mg up to a maximum of 2000 mg capsules will be given orally daily for 28-day treatment period to determine the MTD in Phase 1 of the study. Participants will receive MTD of abiraterone acetate for 12 cycles (28 day each) in Phase 2 of the study. Dexamethasone 0.5 mg will be given orally (If participants have disease progression) daily up to 12 cycles.

    Drug: Abiraterone acetate · Drug: Abiraterone acetate MTD · Drug: Dexamethasone

Interventions

  • Abiraterone 250 mg (1 capsule) up to 2000 mg (8 capsules) once daily, each dose will be tested in sequential order for 28 days to determine the MTD.

    Also known as: CB7630

  • Abiraterone acetate MTD orally for 12 cycles (28 day each).

    Also known as: CB7630

  • Dexamethasone 0.5 mg orally will be given (If participants have disease progression) daily up to 12 cycles.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Confirmed Prostate Specific Antigen (PSA) Response at Week 12

    The PSA response was measured according to PSA working group (PSAWG) criteria. All participants achieving a fall in PSA of greater than 50 percent from baseline, which has been confirmed by a second measurement at least 4 weeks after initial documentation, fulfill criteria for confirmed PSA response.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Number of Participants With Objective Tumor Response

    Number of participants with objective response based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed CR defined as disappearance of all target lesions. Confirmed PR defined as greater than or equal to 30 percent decrease in sum of the longest dimensions (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST. Confirmed responses are those that persist on repeat imaging study greater than or equal to 4 weeks after initial documentation of response.

    Time frame: Baseline up to end of study (1160 days)

  2. Duration of Prostate Specific Antigen (PSA) Response

    Duration of PSA response in participants on abiraterone acetate therapy was measured as the duration between PSA 50 percent decline date and PSA progression date as defined by the PSAWG criteria.

    Time frame: Baseline up to end of study (1160 days)

  3. Duration of Objective Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST)

    Number of participants with objective response based on assessment of confirmed CR or confirmed PR according to RECIST. Confirmed CR defined as disappearance of all target lesions. Confirmed PR defined as greater than or equal to 30 percent decrease in sum of the LD of the target lesions taking as a reference the baseline sum LD according to RECIST. Confirmed responses are those that persist on repeat imaging study greater than or equal to 4 weeks after initial documentation of response.

    Time frame: Baseline up to end of study (1160 days)

  4. Time to Disease Progression

    Disease progression was defined as greater than 25 percent increase in sum of longest diameter of target lesions compared to baseline.

    Time frame: Baseline up to end of study (1160 days)

  5. Overall Survival

    Overall survival was the duration from enrollment to death. For participants who are alive, overall survival was censored at the last contact.

    Time frame: Baseline up to end of study (1160 days)

Other outcomes

  1. Serum Blood Levels of Testosterone

    Concentration of testosterone in blood was measured in nanogram per deciliter (ng/dL).

    Time frame: Baseline, Cycle 2 (within 3 days prior to Day 29)

  2. Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Baseline up to 30 days after the last dose of study medication

  3. Serum Blood Levels of Testosterone Precursors

    Concentration of Cortisol, Aldosterone, Corticosterone, 11-Deoxycortisol, Deoxycorticosterone and Dehydroepiandrostenedione Sulphate (DHEA-S) in blood was measured in nanogram per deciliter (ng/dL).

    Time frame: Baseline, Cycle 2 (within 3 days prior to Day 29)

  4. Time to Prostate Cancer Pain Progression

    The time from start of study treatment to the development/worsening of pain due to prostate cancer requiring one or more of the following treatments: 1- Opioid therapy (therapy with morphine like medicines for 10 out of 14 consecutive days); 2- Glucocorticoid therapy; 3- Initiation of \>= 5 mg of prednisolone for 10 out of 14 consecutive days; 4- Radionuclide therapy; 5- Radiation therapy (x-ray or cobalt treatment); 6- Chemotherapy (treatment of disease by chemical agents). Participants who do not experience prostate cancer pain were censored on their last day on study. Time to prostate cancer pain progression was measured by Kaplan-Meier method.

    Time frame: Baseline up to 12 cycles

  5. Number of Participants With Change From Baseline in Biochemical Bone Markers

    Time frame: Baseline, Cycle 2, 4, 8, 12

  6. Mean Plasma Concentration of Abiraterone

    Time frame: Pre-dose on Day 1, 8 and 15 of Cycle 1, Day 1 of Cycle 2, Day 1 of Cycle 3; 1, 2, 4, 6, 8, 24, 48 and 72 hours after first dose was given

  7. Maximum Observed Plasma Concentration (Cmax) of Abiraterone

    The Cmax is defined as maximum observed analyte concentration.

    Time frame: Pre-dose on Day 1, 8 and 15 of Cycle 1, Day 1 of Cycle 2, Day 1 of Cycle 3; 1, 2, 4, 6, 8, 24, 48 and 72 hours after first dose was given

  8. Time to Reach Maximum Observed Plasma Concentration (Tmax) of Abiraterone

    The Tmax is defined as actual sampling time to reach maximum observed plasma concentration. The analyte concentration associated with Tmax is referred to as Cmax.

    Time frame: Pre-dose on Day 1, 8 and 15 of Cycle 1, Day 1 of Cycle 2, Day 1 of Cycle 3; 1, 2, 4, 6, 8, 24, 48 and 72 hours after first dose was given

  9. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Abiraterone

    Area under the plasma concentration time-curve from time zero to the last quantifiable concentration (AUClast).

    Time frame: Pre-dose on Day 1, 8 and 15 of Cycle 1, Day 1 of Cycle 2, Day 1 of Cycle 3; 1, 2, 4, 6, 8, 24, 48 and 72 hours after first dose was given

  10. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Abiraterone

    AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

    Time frame: Pre-dose on Day 1, 8 and 15 of Cycle 1, Day 1 of Cycle 2, Day 1 of Cycle 3; 1, 2, 4, 6, 8, 24, 48 and 72 hours after first dose was given

  11. Plasma Decay Half-Life (t1/2) of Abiraterone

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: Pre-dose on Day 1, 8 and 15 of Cycle 1, Day 1 of Cycle 2, Day 1 of Cycle 3; 1, 2, 4, 6, 8, 24, 48 and 72 hours after first dose was given

  12. Time to Last Quantifiable Plasma Concentration (Tlast) of Abiraterone

    The actual sampling time of last measurable (non-below the limit of quantification \[BQL\]) analyte concentration. The analyte concentration associated with Tlast is referred to as Clast.

    Time frame: Pre-dose on Day 1, 8 and 15 of Cycle 1, Day 1 of Cycle 2, Day 1 of Cycle 3; 1, 2, 4, 6, 8, 24, 48 and 72 hours after first dose was given

07

Results

Posted Aug 29, 2013

Participant flow

Period 1 (Phase 1)
Participant flow — Period 1 (Phase 1)
Milestone250 mg/Day500 mg/Day750 mg/Day1000 mg/Day2000 mg/Day
Started333423
Completed223252
Not completed110171
Withdrew: Adverse event00050
Withdrew: Death00010
Withdrew: Disease progression110101
Withdrew: Other00010
Period 2 (Phase 2)
Participant flow — Period 2 (Phase 2)
Milestone250 mg/Day500 mg/Day750 mg/Day1000 mg/Day2000 mg/Day
Started122232
Completed00000
Not completed122232
Withdrew: Adverse event00010
Withdrew: Death00011
Withdrew: Disease progression022171
Withdrew: Symptomatic deterioration00010
Withdrew: Other10030

Outcome measures

PrimaryNumber of Participants With Confirmed Prostate Specific Antigen (PSA) Response at Week 12

The PSA response was measured according to PSA working group (PSAWG) criteria. All participants achieving a fall in PSA of greater than 50 percent from baseline, which has been confirmed by a second measurement at least 4 weeks after initial documentation, fulfill criteria for confirmed PSA response.

Time frame:
Baseline, Week 12
Reported as:
Number · Participants
Number of Participants With Confirmed Prostate Specific Antigen (PSA) Response at Week 12
Participants1000 mg AA Monotherapy1000 mg AA Therapy
Number of Participants With Confirmed Prostate Specific Antigen (PSA) Response at Week 121025
SecondaryNumber of Participants With Objective Tumor Response

Number of participants with objective response based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed CR defined as disappearance of all target lesions. Confirmed PR defined as greater than or equal to 30 percent decrease in sum of the longest dimensions (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST. Confirmed responses are those that persist on repeat imaging study greater than or equal to 4 weeks after initial documentation of response.

Time frame:
Baseline up to end of study (1160 days)
Reported as:
Number · Participants
Number of Participants With Objective Tumor Response
Participants1000 mg AA Therapy
Complete response0
Partial response8
SecondaryDuration of Prostate Specific Antigen (PSA) Response

Duration of PSA response in participants on abiraterone acetate therapy was measured as the duration between PSA 50 percent decline date and PSA progression date as defined by the PSAWG criteria.

Time frame:
Baseline up to end of study (1160 days)
Reported as:
Median · Days
Duration of Prostate Specific Antigen (PSA) Response
Days1000 mg AA Therapy
Duration of Prostate Specific Antigen (PSA) Response141 (85 to 235)
SecondaryDuration of Objective Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST)

Number of participants with objective response based on assessment of confirmed CR or confirmed PR according to RECIST. Confirmed CR defined as disappearance of all target lesions. Confirmed PR defined as greater than or equal to 30 percent decrease in sum of the LD of the target lesions taking as a reference the baseline sum LD according to RECIST. Confirmed responses are those that persist on repeat imaging study greater than or equal to 4 weeks after initial documentation of response.

Time frame:
Baseline up to end of study (1160 days)

No measurements were reported for this outcome.

SecondaryTime to Disease Progression

Disease progression was defined as greater than 25 percent increase in sum of longest diameter of target lesions compared to baseline.

Time frame:
Baseline up to end of study (1160 days)

No measurements were reported for this outcome.

SecondaryOverall Survival

Overall survival was the duration from enrollment to death. For participants who are alive, overall survival was censored at the last contact.

Time frame:
Baseline up to end of study (1160 days)

No measurements were reported for this outcome.

Other pre-specifiedSerum Blood Levels of Testosterone

Concentration of testosterone in blood was measured in nanogram per deciliter (ng/dL).

Time frame:
Baseline, Cycle 2 (within 3 days prior to Day 29)
Reported as:
Median · ng/dL
Serum Blood Levels of Testosterone
ng/dL1000 mg AA Therapy
Baseline (n = 23)3 (1 to 10)
Cycle 2 (n = 28)1 (1 to 186)
Other pre-specifiedNumber of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Baseline up to 30 days after the last dose of study medication
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
participants250 mg/Day500 mg/Day750 mg/Day1000 mg/Day2000 mg/Day
AEs333413
SAEs220202
Other pre-specifiedSerum Blood Levels of Testosterone Precursors

Concentration of Cortisol, Aldosterone, Corticosterone, 11-Deoxycortisol, Deoxycorticosterone and Dehydroepiandrostenedione Sulphate (DHEA-S) in blood was measured in nanogram per deciliter (ng/dL).

Time frame:
Baseline, Cycle 2 (within 3 days prior to Day 29)
Reported as:
Median · ng/dL
Serum Blood Levels of Testosterone Precursors
ng/dL1000 mg AA Therapy
Cortisol; Baseline (n = 33)12000 (7000 to 23000)
Cortisol; Cycle 2 (n = 29)4000 (1000 to 11000)
Aldosterone; Baseline (n=33)8 (1 to 32)
Aldosterone; Cycle 2 (n=29)8 (1 to 61)
Corticosterone; Baseline (n=33)193 (4 to 1041)
Corticosterone; Cycle 2 (n=27)6797 (12 to 17148)
11-Deoxycortisol; Baseline (n=31)39 (20 to 233)
11-Deoxycortisol; Cycle 2 (n=25)73 (20 to 836)
Deoxycorticosterone; Baseline (n=32)6 (2 to 31)
Deoxycorticosterone; Cycle 2 (n=28)121 (33 to 1627)
DHEA-S; Baseline (n=32)30000 (15000 to 176000)
DHEA-S; Cycle 2 (n=28)15000 (15000 to 15000)
Other pre-specifiedTime to Prostate Cancer Pain Progression

The time from start of study treatment to the development/worsening of pain due to prostate cancer requiring one or more of the following treatments: 1- Opioid therapy (therapy with morphine like medicines for 10 out of 14 consecutive days); 2- Glucocorticoid therapy; 3- Initiation of \>= 5 mg of prednisolone for 10 out of 14 consecutive days; 4- Radionuclide therapy; 5- Radiation therapy (x-ray or cobalt treatment); 6- Chemotherapy (treatment of disease by chemical agents). Participants who do not experience prostate cancer pain were censored on their last day on study. Time to prostate cancer pain progression was measured by Kaplan-Meier method.

Time frame:
Baseline up to 12 cycles

No measurements were reported for this outcome.

Other pre-specifiedNumber of Participants With Change From Baseline in Biochemical Bone Markers
Time frame:
Baseline, Cycle 2, 4, 8, 12

No measurements were reported for this outcome.

Other pre-specifiedMean Plasma Concentration of Abiraterone
Time frame:
Pre-dose on Day 1, 8 and 15 of Cycle 1, Day 1 of Cycle 2, Day 1 of Cycle 3; 1, 2, 4, 6, 8, 24, 48 and 72 hours after first dose was given

No measurements were reported for this outcome.

Other pre-specifiedMaximum Observed Plasma Concentration (Cmax) of Abiraterone

The Cmax is defined as maximum observed analyte concentration.

Time frame:
Pre-dose on Day 1, 8 and 15 of Cycle 1, Day 1 of Cycle 2, Day 1 of Cycle 3; 1, 2, 4, 6, 8, 24, 48 and 72 hours after first dose was given
Reported as:
Mean · nmol/L
Maximum Observed Plasma Concentration (Cmax) of Abiraterone
nmol/LAbiraterone Acetate 250 mgAbiraterone Acetate 500 mgAbiraterone Acetate 750 mgAbiraterone Acetate 1000 mgAbiraterone Acetate 2000 mg
Maximum Observed Plasma Concentration (Cmax) of Abiraterone219 ± 172.77284 ± 132.381032 ± 344.01571 ± 443.18531 ± 219.02
Other pre-specifiedTime to Reach Maximum Observed Plasma Concentration (Tmax) of Abiraterone

The Tmax is defined as actual sampling time to reach maximum observed plasma concentration. The analyte concentration associated with Tmax is referred to as Cmax.

Time frame:
Pre-dose on Day 1, 8 and 15 of Cycle 1, Day 1 of Cycle 2, Day 1 of Cycle 3; 1, 2, 4, 6, 8, 24, 48 and 72 hours after first dose was given
Reported as:
Mean · hours
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Abiraterone
hoursAbiraterone Acetate 250 mgAbiraterone Acetate 500 mgAbiraterone Acetate 750 mgAbiraterone Acetate 1000 mgAbiraterone Acetate 2000 mg
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Abiraterone2.050 ± 0.022.588 ± 1.021.709 ± 0.413.159 ± 1.792.672 ± 1.14
Other pre-specifiedArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Abiraterone

Area under the plasma concentration time-curve from time zero to the last quantifiable concentration (AUClast).

Time frame:
Pre-dose on Day 1, 8 and 15 of Cycle 1, Day 1 of Cycle 2, Day 1 of Cycle 3; 1, 2, 4, 6, 8, 24, 48 and 72 hours after first dose was given
Reported as:
Mean · hours*nmol/L
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Abiraterone
hours*nmol/LAbiraterone Acetate 250 mgAbiraterone Acetate 500 mgAbiraterone Acetate 750 mgAbiraterone Acetate 1000 mgAbiraterone Acetate 2000 mg
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Abiraterone1253 ± 519.781334 ± 731.474294 ± 1295.204371 ± 3427.544754 ± 1659.13
Other pre-specifiedArea Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Abiraterone

AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

Time frame:
Pre-dose on Day 1, 8 and 15 of Cycle 1, Day 1 of Cycle 2, Day 1 of Cycle 3; 1, 2, 4, 6, 8, 24, 48 and 72 hours after first dose was given
Reported as:
Mean · hours*nmol/L
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Abiraterone
hours*nmol/LAbiraterone Acetate 250 mgAbiraterone Acetate 500 mgAbiraterone Acetate 750 mgAbiraterone Acetate 1000 mgAbiraterone Acetate 2000 mg
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Abiraterone1369 ± 505.391448 ± 749.014537 ± 1333.424615 ± 3660.484983 ± 1755.24
Other pre-specifiedPlasma Decay Half-Life (t1/2) of Abiraterone

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
Pre-dose on Day 1, 8 and 15 of Cycle 1, Day 1 of Cycle 2, Day 1 of Cycle 3; 1, 2, 4, 6, 8, 24, 48 and 72 hours after first dose was given
Reported as:
Mean · hour
Plasma Decay Half-Life (t1/2) of Abiraterone
hourAbiraterone Acetate 250 mgAbiraterone Acetate 500 mgAbiraterone Acetate 750 mgAbiraterone Acetate 1000 mgAbiraterone Acetate 2000 mg
Plasma Decay Half-Life (t1/2) of Abiraterone11.6 ± 10.149.5 ± 7.0210.8 ± 5.9110.6 ± 4.6912.0 ± 2.29
Other pre-specifiedTime to Last Quantifiable Plasma Concentration (Tlast) of Abiraterone

The actual sampling time of last measurable (non-below the limit of quantification \[BQL\]) analyte concentration. The analyte concentration associated with Tlast is referred to as Clast.

Time frame:
Pre-dose on Day 1, 8 and 15 of Cycle 1, Day 1 of Cycle 2, Day 1 of Cycle 3; 1, 2, 4, 6, 8, 24, 48 and 72 hours after first dose was given

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
250 mg/Day—2/3 (66.7%)3/3 (100%)
500 mg/Day—2/3 (66.7%)3/3 (100%)
750 mg/Day—0/3 (0%)3/3 (100%)
1000 mg/Day—20/42 (47.6%)41/42 (97.6%)
2000 mg/Day—2/3 (66.7%)3/3 (100%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
Event250 mg/Day500 mg/Day750 mg/Day1000 mg/Day2000 mg/Day
VomitingGastrointestinal disorders1/30/30/31/420/3
Oedema peripheralGeneral disorders0/30/30/30/421/3
PainGeneral disorders1/30/30/30/420/3
PyrexiaGeneral disorders0/31/30/31/420/3
InfectionInfections and infestations0/31/30/30/420/3
Infective exacerbation of chronic obstructive airways diseaseInfections and infestations1/30/30/30/420/3
Lower respiratory tract infectionInfections and infestations1/30/30/31/420/3
SepsisInfections and infestations0/31/30/32/420/3
Urinary tract infectionInfections and infestations0/31/30/31/420/3
DehydrationMetabolism and nutrition disorders0/31/30/31/420/3
Most frequent other events
Showing 10 of 117
Most frequent other events
Event250 mg/Day500 mg/Day750 mg/Day1000 mg/Day2000 mg/Day
NauseaGastrointestinal disorders3/30/32/35/421/3
Oedema peripheralGeneral disorders0/30/31/319/423/3
HypokalaemiaMetabolism and nutrition disorders1/32/33/334/421/3
ConstipationGastrointestinal disorders2/30/31/311/420/3
VomitingGastrointestinal disorders2/30/31/38/421/3
FatigueGeneral disorders2/31/32/321/422/3
Pitting oedemaGeneral disorders0/30/30/32/422/3
AnorexiaMetabolism and nutrition disorders0/32/31/33/420/3
ArthralgiaMusculoskeletal and connective tissue disorders0/30/32/312/420/3
Back painMusculoskeletal and connective tissue disorders0/30/32/38/420/3

Baseline characteristics

Age, Continuous
Age, Continuous(years)250 mg/Day500 mg/Day750 mg/Day1000 mg/Day2000 mg/DayTotal
Mean61.3 ± 9.0768.7 ± 10.4176 ± 8.1970.4 ± 7.4268 ± 12.1769.9 ± 8.04
Sex: Female, Male
Sex: Female, Male(Participants)250 mg/Day500 mg/Day750 mg/Day1000 mg/Day2000 mg/DayTotal
Female000000
Male33342354
08

Study locations

1 site
  • Sutton, United Kingdom
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2005, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 4 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2007
First posted
May 15, 2007
Start
Nov 2005
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Results first posted
Aug 29, 2013
Last update
Mar 27, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00473512
Responsible party
Sponsor
First posted
May 15, 2007
Start date
Nov 2005
Primary completion
Nov 2008
Completion
Nov 2008
Results posted
Aug 29, 2013
Last update
Mar 27, 2014

Study contacts

Cougar Biotechnology Clinical Trial
study director · Cougar Biotechnology, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abiraterone Acetate

Start the discussion